Sexual Dysfunctions, Psychological Clinical Trial
Official title:
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties
Verified date | May 2017 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to pilot test and determine the feasibility of a
psychoeducational intervention (PED) we recently developed in a group format for women with
acquired sexual arousal disorder (FSAD).
HYPOTHESES:
- 1 - Compared to baseline measures, the PED will result in significant improvement in
self-report measures of: (a) subjective sexual arousal; (b) perception of genital
arousal/genital sensitivity; (c) orgasmic experience; (d) sexual desire; (e) sexual
distress; (f) relationship satisfaction; (g) depressive symptoms; and (h) quality of
life.
- 2 - It is unknown what effect the PED will have on actual physiological sexual arousal.
- 3 - The group format will be a feasible and cost-effective method of delivering
empirically supported treatment to women with sexual arousal difficulties and will
contribute towards meeting the needs for sexual health care for women on the clinic
wait-list at the BC Centre for Sexual Medicine.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 2008 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Women between the ages of 19 and 65 who are currently seeking treatment at the BC Centre for Sexual Medicine; 2. Women who are determined to meet criteria for acquired Female Sexual Arousal Disorder (FSAD); 3. Must be proficient in English and willing to take part in group sessions. Exclusion Criteria: Women who do not meet criteria for FSAD, as determined by the Co-Investigators, will not be informed about the study. In addition, women who might not be suitable for group therapy will be excluded. |
Country | Name | City | State |
---|---|---|---|
Canada | BC Centre for Sexual Medicine | Vancouver | British Columbia |
Canada | UBC Sexual Health Lab, Vancouver Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Upon completion of data analysis, establishment of the efficacy of Psychoeducational intervention (PED) in group format for the treatment women with Female Sexual Arousal Disorder will be determined. | following completion of data collection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00996164 -
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00996372 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
|
Phase 3 | |
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
Completed |
NCT04792177 -
Internet-based Emotion Regulation Intervention for Sexual Health
|
N/A | |
Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
Completed |
NCT00491829 -
Flibanserin Versus Placebo in Premenopausal Women With HSDD
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Recruiting |
NCT05489133 -
Early Psychological Intervention After Rape
|
N/A | |
Completed |
NCT03775239 -
Mindfulness as Treatment of Sexological Problems
|
N/A | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT01188603 -
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 1 | |
Completed |
NCT01771237 -
HIV Prevention Among Vulnerable Male Youth
|
N/A | |
Completed |
NCT00360555 -
A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360243 -
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
|
Phase 3 | |
Completed |
NCT00360529 -
24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
Terminated |
NCT01040208 -
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress
|
Phase 3 | |
Terminated |
NCT01057901 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
|
Phase 3 |